skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Nome da Publicação: Clinical Cancer Research remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Brentuximab Vedotin
Brentuximab Vedotin
Material Type:
Artigo 		Adicionar ao Meu Espaço

Brentuximab Vedotin

Deng, Changchun ; Pan, Beiqing ; O'Connor, Owen A

Clinical cancer research, 2013, Vol.19 (1), p.22-27 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
2
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

O'Connor, Owen A. ; Stewart, A. Keith ; Vallone, Marcy ; Molineaux, Christopher J. ; Kunkel, Lori A. ; Gerecitano, John F. ; Orlowski, Robert Z.

Clinical cancer research, 2009-11, Vol.15 (22), p.7085-7091 [Periódico revisado por pares]

United States: American Association for Cancer Research

Texto completo disponível

Citações Citado por
3
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Shah, Jatin J ; Jakubowiak, Andrzej J ; O'Connor, Owen A ; Orlowski, Robert Z ; Harvey, R Donald ; Smith, Mitchell R ; Lebovic, Daniel ; Diefenbach, Catherine ; Kelly, Kevin ; Hua, Zhaowei ; Berger, Allison J ; Mulligan, George ; Faessel, Hélène M ; Tirrell, Stephen ; Dezube, Bruce J ; Lonial, Sagar

Clinical cancer research, 2016-01, Vol.22 (1), p.34-43 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
4
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

Amengual, Jennifer E ; Johannet, Paul ; Lombardo, Maximilian ; Zullo, Kelly ; Hoehn, Daniela ; Bhagat, Govind ; Scotto, Luigi ; Jirau-Serrano, Xavier ; Radeski, Dejan ; Heinen, Jennifer ; Jiang, Hongfeng ; Cremers, Serge ; Zhang, Yuan ; Jones, Simon ; O'Connor, Owen A

Clinical cancer research, 2015-10, Vol.21 (20), p.4663-4675 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
5
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Kahl, Brad S ; Hamadani, Mehdi ; Radford, John ; Carlo-Stella, Carmelo ; Caimi, Paolo ; Reid, Erin ; Feingold, Jay M ; Ardeshna, Kirit M ; Solh, Melhem ; Heffner, Leonard T ; Ungar, David ; He, Shui ; Boni, Joseph ; Havenith, Karin ; O'Connor, Owen A

Clinical cancer research, 2019-12, Vol.25 (23), p.6986-6994 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
6
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Ansell, Stephen M ; Maris, Michael B ; Lesokhin, Alexander M ; Chen, Robert W ; Flinn, Ian W ; Sawas, Ahmed ; Minden, Mark D ; Villa, Diego ; Percival, Mary-Elizabeth M ; Advani, Anjali S ; Foran, James M ; Horwitz, Steven M ; Mei, Matthew G ; Zain, Jasmine ; Savage, Kerry J ; Querfeld, Christiane ; Akilov, Oleg E ; Johnson, Lisa D S ; Catalano, Tina ; Petrova, Penka S ; Uger, Robert A ; Sievers, Eric L ; Milea, Anca ; Roberge, Kathleen ; Shou, Yaping ; O'Connor, Owen A

Clinical cancer research, 2021-04, Vol.27 (8), p.2190-2199 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
7
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma

Zullo, Kelly M ; Guo, Yige ; Cooke, Laurence ; Jirau-Serrano, Xavier ; Mangone, Michael ; Scotto, Luigi ; Amengual, Jennifer E ; Mao, Yinghui ; Nandakumar, Renu ; Cremers, Serge ; Duong, Jimmy ; Mahadevan, Daruka ; O'Connor, Owen A

Clinical cancer research, 2015-09, Vol.21 (18), p.4097-4109 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
8
Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context
Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context
Material Type:
Artigo 		Adicionar ao Meu Espaço

Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context

O'Connor, Owen A ; Tobinai, Kensei

Clinical cancer research, 2014-10, Vol.20 (20), p.5173-5181 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
9
Pralatrexate Pharmacology and Clinical Development
Pralatrexate Pharmacology and Clinical Development
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pralatrexate Pharmacology and Clinical Development

MARCHI, Enrica ; MANGONE, Michael ; ZULLO, Kelly ; O'CONNOR, Owen A

Clinical cancer research, 2013-12, Vol.19 (24), p.6657-6661 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
10
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

ALSINA, Melissa ; TRUDEL, Suzanne ; FURMAN, Richard R ; ROSEN, Peter J ; O'CONNOR, Owen A ; COMENZO, Raymond L ; WONG, Alvin ; KUNKEL, Lori A ; MOLINEAUX, Christopher J ; GOY, Andre

Clinical cancer research, 2012-09, Vol.18 (17), p.4830-4840 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.